Clin Osteol 2015; 20(2): 46-56

Management of proximal femoral fracture patiens and secondary prevention of fractures II. Secondary antiosteoporotic careGuidelines

J. Štěpán, J. Vaculík, V. Palička, P. Dungl, V. Vyskočil, K. Pavelka

Hip fractures disproportionately affect elderly male and female patients, and may result in impairment of mobility, loss of quality of life, increased health resource utilization and even in death. Despite strong evidence indicating that the occurrence of a hip fracture increases the risk of other osteoporotic fractures including recurrent hip fractures, secondary prevention of fractures in older patients with hip fractures is not adequately provided. One explanation for this decrease is the perception that it is too late to alter the course of the disease in its late stage. The management of such patients should include assessing clinical diagnosis, treating osteoporosis and preventing falls. Based on clinical trials and experience, this collective position of professional societies reviews the anti-fracture mea­ sures and efficacy and safety of antiosteoporotic agents in this high-risk elderly population of patients with recent low trauma hip frac­ tures. Available pharmacological therapies for the treatment of osteoporosis include calcium and vitamin D, antiresorptive drugs such as bisphosphonates and denosumab, and the bone forming drug teriparatide. Many elderly patients with establi multiple comorbid conditions, and demonstrated drug safety in this frail population is critically important.

Keywords: osteoporosis, fracture ofproximal heed offemur, therapy

Published: December 11, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štěpán J, Vaculík J, Palička V, Dungl P, Vyskočil V, Pavelka K. Management of proximal femoral fracture patiens and secondary prevention of fractures II. Secondary antiosteoporotic care. Osteologický bulletin. 2015;20(2):46-56.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Haentjens P, Magaziner J, Colon-Emeric CS et al. Meta-analysis: excess mo ty after hip fracture among older women and men. Ann Intern Med 2010;152(6): 380-390. Go to original source...
    2. Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P. Functional outcome and quality of life following hip fracture in elderly wo a prospective controlled study. Osteoporos Int 2004;15(2):87-94. Go to original source...
    3. Hallberg I, Bachrach-Lindstrom M, Hammerby S, Toss G, Ek AC. Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. Musculoskelet Disord 2009;10:135. Go to original source...
    4. Štěpán J, Šmíd M, Prokeš M et al. Ekonomické aspekty osteoporózy. [Economic aspects of osteoporosis]. Cas Lek Cesk 1998;137(23):707-715.
    5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-relat States, 2005-2025. J Bone Miner Res 2007;22(3):465^75. Go to original source...
    6. Cooper C. The crippling consequenc of life. Am J Med 1997;103(2a):12-17. Go to original source...
    7. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E. BMD, clinical risk tors and their combination for hip fracture prevention. Osteoporos Int 2009; 20(10):1675-1682. Go to original source...
    8. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the terature and statistical synthesis. J Bone Miner Res 2000;15(4):721-739. Go to original source...
    9. Omsland TK, Emaus N, Tell GS et al. Ten-year risk of second hip fracture. A NOREPOS study. Bone 2013;52(1):493^97. Go to original source...
    10. Vochteloo AJ, Borger van der Burg BL, Roling MA et al. Contralateral hip frac­ tures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients. Arch Orthop Trauma Surg 2012;132(8):1191-1197. Go to original source...
    11. Skála-Rosenbaum J, Džupa V, Bartoška R, Říha D, Waldauf P, Bača V. Subsequent contralateral hip fractures: can at-risk patients be identified? An ob­ servational study of 5,102 patients. Int Orthop 2015. Go to original source...
    12. Berry SD, Samelson EJ, Hannan MT et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med 2007;167(18):1971-1976. Go to original source...
    13. Papaioannou A, Wiktorowicz M, Adachi JD, Goeree R, Papadimitropoulos E. Mortality, independence in living, and re-fracture, one in Canadians. J Soc Obstet Gynaecol Can 2000;22:591-597. Go to original source...
    14. von Friesendorff M, Besjakov J, Akesson K. Long-term survival and fr after hip fracture: a 22-year follow-up in women. J Bone Miner Res 2008; 23(11):1832-1841. Go to original source...
    15. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res 2009;24(7):1299-1307. Go to original source...
    16. Papaioannou A, Kennedy CC, Ioannidis G et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 2008;19(4):581-587. Go to original source...
    17. Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in pa­ tients with recent fractures: a nationwide analysis of prescription rates and pers tence. Osteoporos Int 2009;20(2):299-307. Go to original source...
    18. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis Medication Use after Hip Fracture in U.S. Patients between 2002 and 2011. J Bone Miner Res 2014. Go to original source...
    19. Kim SC, Kim MS, Sanfelix-Gimeno G et al. Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. Am J Med 2015. Go to original source...
    20. Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-1809. Go to original source...
    21. Misof BM, Fratzl-Zelman N, Paschalis EP, Roschger P, Klaushofer K. Long-term safety of antiresorptive treatment: bone material, matrix and mineralization as­ pects. BoneKEy Rep 2015;4. Go to original source...
    22. Reid IR. Efficacy, effectiveness and side effects of medications used to prev fractures. J Intern Med 2014. Go to original source...
    23. WHO. Assessment offracture risk and its application to screening forpostmeno­ pausal osteoporosis. Report of a WHO Study Group. Geneva: World Health Organisation; 1994.
    24. Bliuc D, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Risk of Subsequent Fractures and Mortality in Elderly Women and Men With Fragility Fractures With and Without Osteoporotic Bone Density: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2014. Go to original source...
    25. Nguyen TV, Center JR, Eisman JA Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res 2005;20(7):1195-1201. Go to original source...
    26. Leslie WD, Majumdar SR, Morin SN, Lix LM. Why does rate ofbone density loss not predict fracture risk? J Clin Endocrinol Metab 2015;100(2):679-683. Go to original source...
    27. Langsetmo L, Goltzman D, Kovacs CS et al. Repeat low-trauma fractures occur frequently among men and women who have osteopenic BMD. J Bone Miner Res 2009;24(9):1515-1522. Go to original source...
    28. Siris ES, Miller PD, Barrett Connor E et al. Identification and fracture outc of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286(22):2815-2822. Go to original source...
    29. WHO. Assessment of osteoporosis at the primary health care level. Report of a WHO Study Group. Sheffield: University of Sheffield Medical School, UK; 2007.
    30. Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. Osteoporos Int 2014;25(1):1-21. Go to original source...
    31. Bauer DC, Garnero P, Harrison SL et al. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res 2009; 24(12):2032-2038. Go to original source...
    32. Rizzoli R, Ammann P, Chevalley T, Bonjour JP. Protein intake and bone diso in the elderly. Joint Bone Spine 2001;68(5):383-392. Go to original source...
    33. Schurch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum insulin-like growth factor-I levels and attenuate pro­ ximal femur bone loss in patients with recent hip fracture. A randomized, blind, placebo-controlled trial. Ann Intern Med 1998;128(10):801-809. Go to original source...
    34. Murad MH, Drake MT, Mullan RJ et al. Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis. J Clin Endocrinol Metab 2012;97:1871-1880. Go to original source...
    35. Reid IR, Bo 2014;77(1):1-3.
    36. Adami S, Giannini S, Bianchi G et al. Vitamin D status and resp in post-menopausal osteoporosis. Osteoporos Int 2009;20(2):239-244. Go to original source...
    37. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the eld consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22(4):477-501. Go to original source...
    38. Bischoff-Ferrari HA, Can U, Staehelin HB et al. Severe vitamin D deficienc Swiss hip fracture patients. Bone 2008;42(3):597-602. Go to original source...
    39. LeBoff MS, Hawkes WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int 2008;19(9):1283-1290. Go to original source...
    40. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Daws Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293(18):2257-2264. Go to original source...
    41. Sawka AM, Ismaila N, Cranney A et al. A scoping review of strategies for th vention of hip fracture in elderly nursing home residents. PLoS ONE 2010; 5(3):e9515. Go to original source...
    42. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-meno­ pausal osteoporosis. Cochrane Database Syst Rev 2009(2):CD000227. Go to original source...
    43. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or cal­ cium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007; 370(9588):657-666. Go to original source...
    44. Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for se­ condary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-control­ led trial. Lancet 2005;365(9471):1621-1628. Go to original source...
    45. Bischoff-Ferrari HA, Willett WC, Wong JB et al. Prevention of nonvertebr tures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169(6):551-561. Go to original source...
    46. Prestwood KM, P^nnullo AM, Kenny AM, Pilbeam CC, Raisz LG. The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int 1996;6(4):314-319. Go to original source...
    47. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitam supplementation: evidence from a comparative metaanalysis of randomized con­ trolled trials. J Clin Endocrinol Metab 2007;92(4):1415-1423. Go to original source...
    48. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ. A randomised, con­ trolled comparison of different calcium and vitamin D supplementation reg in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. Age Ageing 2004;33(1):45-51. Go to original source...
    49. Bischoff Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson Hughes B. Fracture prevention with vitamin D supplementation: of randomized controlled trials. JAMA 2005;293(18):2257-2264. Go to original source...
    50. van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Bo Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol 2010;162(4):805-811. Go to original source...
    51. Rosa J. Doporučené postupy pro diagnosti rózy II. Osteologický Bull 2007;12(2):74-81.
    52. Ensrud KE, Black DM, Palermo L et al. Treatment with alendronate prevents frac­ tures in women at highest risk: re Intern Med 1997;157(22):2617-2624. Go to original source...
    53. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344(5):333-340. Go to original source...
    54. Osaki M, Tatsuki K, Hashikawa T et al. Beneficial effect of risedronate for pre­ venting recurr 23(2):695-703.
    55. Boonen S, Black DM, Colon-Emeric CS et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmeno­ pausal w 292-299.
    56. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma, deltaT-cell proliferation and activation in vitro. J Bone Miner Res 2004;19(2):278-288. Go to original source...
    57. Shane E, Burr D, Abrahamsen B et al. Atypical subtrochanteric and diaphyseal fe­ moral fractures: second report of a task force ofthe american society for bone mineral research. J Bone Miner Res 2014;29(1):1-23. Go to original source...
    58. Khan AA, Morrison A, Hanley DA et al. Diagnosis and management of osteone­ crosis of the jaw: a Res 2015;30(1):3-23.
    59. Boonen S, Adachi JD, Man Z et al. Treatment with denosumab reduces the inci­ dence of new vertebral and hip fractures in p J Clin Endocrinol Metab 2011;96(6):1727-1736. Go to original source...
    60. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduce risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-2822. Go to original source...
    61. Jonville-Bera AP, Autret-Leca E. [Adverse drug reac (Protelos®) in France]. Presse Med 2011;40(10):e453-62. Go to original source...
    62. Eriksen EF, Keaveny TM, Gallagher ER, Krege JH. Literature review: of teriparatide therapy at the hip in patients with osteoporosis. Bone 2014;67:246-256. Go to original source...
    63. Aspenberg P, Genant HK, Johansson T et al. Teriparatide for acceleration of fr ture repair in humans: a prospective, randomized, double-blind study of 102 post­ menopausal women with distal radial fractures. J Bone Miner Res 2010; 25(2):404-414. Go to original source...
    64. Walsh JB, Lems WF, Karras D et al. Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2012;90(5):373-383. Go to original source...
    65. Nikolaou VS, Efstathopoulos N, Kontakis G, Kanakaris NK, Giannoudis PV. The influence of osteoporosis in femoral fracture healing time. Injury 2009; 40(6):663-668. Go to original source...
    66. Gorter EA, Hamdy NA, Appelman-Dijkstra NM, Schipper IB. The role of vita­ min D in human fracture healing: a systematic review of the literature. Bone 2014; 64:288-297. Go to original source...
    67. Gong HS, Song CH, Lee YH, Rhee SH, Lee HJ, Baek GH. Early initiation of bis­ phosphonate does not affect healing and outcomes of volar plate fixation of osteo­ porotic distal radial fractures. J Bone Joint Surg Am 2012;94(19):1729-1736. Go to original source...
    68. Adami S, Libanati C, Boonen S et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am 2012;94(23):2113-2119. Go to original source...
    69. Gerstenfeld LC, Sacks DJ, Pelis M et al. Comparison of effects of the b phonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24(2):196-208. Go to original source...
    70. Larsson S, Fazzalari NL. Anti-osteo Orthop Trauma Surg 2014;134(2):291-297. Go to original source...
    71. Aspenberg P, Johansson T. Teriparatide improves early callus formation radial fractures. Acta Orthop 2010;81(2):234-236. Go to original source...
    72. Zhang D, Potty A, Vyas P, Lane J. The Role of Recombinant Pth in Human Fracture Healing: A Systematic Review. J Orthop Trauma 2013. Go to original source...
    73. Ellegaard M, Kringelbach T, Syberg S, et al. The effect of PTH(1-34) on frac re healing during different loading conditions. J Bone Miner Res 2013;28(10): 2145-2155. Go to original source...
    74. Jbichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 2011;93:1583-1587. Go to original source...
    75. Vaculík J, Dungl P, Malkus T et al. Péče o pacienty se zlomeninou horního k ce stehenní kosti. I. Ortopedická péče. Doporučené postupy České revmatologické společnosti a Společnosti pro metabolická onemocnění skeletu. Čes Revmatologie 2009;17(3):134-144.
    76. Langdahl BL, Rajzbaum G, Jakob F et al. Reduction in fracture rate and back p and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2009;85(6):484^93. Go to original source...
    77. Eriksen EF, Lyles KW, Colon-Emeric CS et al. Antifracture efficacy and reduc­ tion of mortality in relation to timing of the first dose of zoledronic acid after fracture. J Bone Miner Res 2009;24(7):1308-1313. Go to original source...
    78. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81(8):1013-1022. Go to original source...
    79. Ganda K, Schaffer A, Seibel MJ. Predictors of re-fracture amongst patients ma­ naged within a secondary fracture prevention program: a 7-year prospective study. Osteoporos Int 2015;26(2):543-551. Go to original source...
    80. Eisenberg DF, Placzek H, Gu T, Krishna A, Tulsi BB. Cost and consequences of noncompliance to oral bisphosphonate treatment. Journal of managed care & spe­ cialty pharmacy 2015;21(1):56-65. Go to original source...
    81. LeBlanc ES, Rosales AG, Balasubramanian A, et al. Risk factors for fracture among current, persistent users of bisphosphonates. Osteoporos Int 2015;26(2): 713-725. Go to original source...
    82. Kannus P, Parkkari J, Niemi S et al. Prevention of hip fractu with use of a hip protector. N Engl J Med 2000;343(21):1506-1513. Go to original source...
    83. Kiel DP, Magaziner J, Zimmerman S et al. Efficacy of a hip protector to prev hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007;298(4):413-422. Go to original source...
    84. Cryer C, Knox A, Stevenson E. Factors associated with hip prot among older people in residential care. Inj Prev 2008;14(1):24-29. Go to original source...
    85. Oliver D, Connelly JB, Victor CR et al. Strategies to prevent falls and fr hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ 2007;334(7584):82. Go to original source...
    86. Cameron ID, Kurrle S, Quine S et al. Increasing adherence with the use o tectors for older people living in the community. Osteoporos Int 2011;22(2): 617-626. Go to original source...
    87. Close JC. How can you prevent falls and subsequent fractures? Best Pract Res Rheumatol 2013;27(6):821-834. Go to original source...
    88. Cumming RG, Thomas M, Szonyi G et al. Home visits by an occupational thera­ pist for assessment and modification of environmental hazards: a randomized trial of falls prevention. J Am Geriatr Soc 1999;47(12):1397-1402. Go to original source...
    89. Madureira MM, Takayama L, Gallinaro AL, Caparbo VF, Costa RA, Pereira RM. Balance training program is highly effective in improving functional status an ducing the risk of falls in elderly women with osteoporosis: a randomized con­ trolled trial. Osteoporos Int 2007;18(4):419-425. Go to original source...
    90. Robertson MC, Devlin N, Gardner MM, Campbell AJ. Effectiveness and econo­ mic evaluation of a nurse delivered home exercise programme to prevent falls. 1: Randomised controlled trial. BMJ 2001;322(7288):697-701. Go to original source...
    91. Singh NA, Quine S, Clemson LM et al. Effects ofhigh-intensity progressive resis­ tance training and targeted multidisciplinary treatment of frailty on mortality nursing home admissions after hip fracture: a randomized controlled trial. J Am Med Dir Assoc 2012;13(1):24-30. Go to original source...
    92. Duque G, Troen BR. Understanding the mechanisms of senile osteoporosis: new facts for a major geriatric syndrome. J Am Geriatr Soc 2008;56(5):935-941. Go to original source...
    93. Myint MW, Wu J, Wong E et al. Clinical benefits of oral nutritional supplemen­ tation for elderly hip fracture patients: a single blind randomised controlled tri Age Ageing 2013;42(1):39^5. Go to original source...
    94. Wyers CE, Reijven PL, Evers SM et al. Cost-effectiveness of nutritional inter­ vention in elderly subjects after hip fracture. A randomized controlled trial. Osteoporos Int 2013;24(1):151-162. Go to original source...
    95. Richy F, Dukas L, Schacht E. Differential effects of D-hormone analogs and na­ tive vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue 2008;82(2):102-107. Go to original source...
    96. Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteopo­ rosis medications in elderly patients with fractures. Am J Med 2003;115(5): 398 400. Go to original source...
    97. Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteo­ porosis among postmenopausal women following a fracture. Arch Intern Med 2003;163(17):2052-2057. Go to original source...
    98. Vytřísalová M, Fuksa L, Palička V et al. Adherence to osteoporosis guideline: vey among Czech general practitioners. Cent Eur J Med 2014;9(5):687-693. Go to original source...
    99. McLellan AR, Wolowacz SE, Zimovetz EA et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effecti­ veness evaluation based on data collected over 8 years of service provision. Osteoporos Int 2011;22(7):2083-2098. Go to original source...
    100. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic ac of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-1822. Go to original source...
    101. Boonen S, Marin F, Mellstrom D et al. Safety and efficacy of teriparatide derly women with established osteoporosis: bone anabolic therapy from a geria­ tric perspective. J Am Geriatr Soc 2006;54(5):782-789. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.